P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA

Por Clement, P.M., Caenepeel, C., Beuselinck, B., Bechter, O.E.
Publicado em 2014

P16.07 BEVACIZUMAB AS PALLIATIVE TREATMENT OF FAMILIAL SCHWANNOMATOSIS

Por Clement, P.M., Blockmans, D., Bechter, O.E., Van Calenbergh, F., Legius, E.
Publicado em 2014

Whole-body diffusion-weighted imaging for staging lymphoma: are apparent diffusion coefficient derived histogram parameters useful for lesion characterisation?

Por De Paepe, K, De Keyzer, F, Wolter, P, Bechter, O, Janssens, A, Dierickx, D, Oyen, R, Verhoef, G, Vandecaveye, V
Publicado no Cancer Imaging (2014)

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial

Por De Smedt, J., Van Kelst, S., Boecxstaens, V., Stas, M., Bogaerts, K., Vanderschueren, D., Aura, C., Vandenberghe, K., Lambrechts, D., Wolter, P., Bechter, O., Nikkels, A., Strobbe, T., Emri, G., Marasigan, V., Garmyn, M.
Publicado no BMC Cancer (2017)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Por Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S., Larkin, J.
Publicado no N Engl J Med (2017)